By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


UCB Group 

Allée de la Recherche, 60

Brussels    1070  Belgium
Phone: (32-2) 559-99-99 Fax: (32-2) 559-99-00


Company News
New Indication For VIMPAT® (Lacosamide): UCB Group (UCBJF.PK)'s Anti-Epileptic Drug Approved By FDA As Monotherapy In The Treatment Of Patients With Partial-Onset Seizures 9/2/2014 11:37:51 AM
UCB Group (UCBJF.PK) And Dermira Enter Into Strategic Collaboration In Dermatology To Broaden Patient Access To Cimzia® (Certolizumab Pegol) 7/3/2014 6:38:35 AM
Beryllium Strengthens Collaboration With Key Partner, UCB Group (UCBJF.PK) 5/20/2014 10:17:06 AM
Biopharma Learns From Marvel, UCB Group (UCBJF.PK) And Massachusetts Institute of Technology (MIT) Begin Real Life Search For "X-Men" 4/30/2014 7:13:29 AM
UCB Group (UCBJF.PK) Not For Sale As Billionaire Shareholder Awaits Reward 12/2/2013 8:06:35 AM
Evotec AG (EVTG.F) Achieves First Milestones in Multi-Target Deal With UCB Group (UCBJF.PK) 10/28/2013 9:50:59 AM
UCB Group (UCBJF.PK)'s Cimzia® (Certolizumab Pegol) Approved by FDA for Treatment of Adults With Active Ankylosing Spondylitis 10/18/2013 8:56:49 AM
Immunomedics, Inc. (IMMU) Reports That UCB Group (UCBJF.PK) Announces New Results From Phase 2B Open-Label Extension Study Evaluating the Long-Term Effects of Epratuzumab in SLE 6/13/2013 8:49:32 AM
UCB Group (UCBJF.PK) Chooses Emerson Automation and Operations Management Technologies for One of Europe’s Largest Biotech Plants 1/9/2013 10:12:20 AM
UCB Group (UCBJF.PK) Announces Data on Cimzia® (certolizumab pegol) for Patients With Moderate to Severe Rheumatoid Arthritis at American College of Rheumatology 2012 Congress 11/13/2012 10:55:38 AM